Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05728957 · ClinicalTrials.gov registry record
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
A clinical trial of Kidney Tumor and Renal Benign Neoplasm, sponsored by Loyola University.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05728957 is a study of Kidney Tumor and Renal Benign Neoplasm that is actively recruiting participants, run by Loyola University. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05728957, a study of Kidney Tumor and Renal Benign Neoplasm, is actively recruiting participants, sponsored by Loyola University.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors. To estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT/CT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC. Participants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.
Conditions Studied
Study Locations (1)
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-02-01 |
| Est. Completion | 2033-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05728957
The ClinicalTrials.gov registry entry for NCT05728957 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Kidney Tumor appearing as the primary indexed condition, and to 0 interventions.
NCT05728957 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05728957 about?
NCT05728957 is a clinical study titled "Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors". The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor. The main objectives are: To estimate and co...
What is the current status of trial NCT05728957?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2023-02-01. Estimated completion is 2033-12.
What conditions does trial NCT05728957 study?
This clinical trial studies the following conditions: Kidney Tumor, Renal Benign Neoplasm, Renal Malignant Tumor.
Who is sponsoring clinical trial NCT05728957?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05728957 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.